Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis

World Journal of Gastroenterology

Volumn 21, Issue 6, 2015, Pages 1880-1886

  Kawakami, Ken ^a   Inoue, Takuya ^a   Murano, Mitsuyuki ^a   Narabayashi, Ken ^a   Nouda, Sadaharu ^a   Ishida, Kumi ^a   Abe, Yosuke ^a   Nogami, Koji ^b   Hida, Nobuyuki ^b   Yamagami, Hirokazu ^c   Watanabe, Kenji ^c   Umegaki, Eiji ^a   Nakamura, Shiro ^b   Arakawa, Tetsuo ^c   Higuchi, Kazuhide ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Inflammatory bowel disease; Rapid induction therapy; Steroid refractory ulcerative colitis; Tacrolimus; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; CREATININE; GLUCOSE; MERCAPTOPURINE; STEROID; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CHRONOTHERAPY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; LICHTIGER CLINICAL ACTIVITY INDEX; MALE; MEAL; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; REMISSION; STEROID THERAPY; TIME TO TREATMENT; TREATMENT RESPONSE; TREMOR; ULCERATIVE COLITIS; BLOOD; CLINICAL TRIAL; COLITIS, ULCERATIVE; DRUG MONITORING; INDUCTION CHEMOTHERAPY; JAPAN; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; COLITIS, ULCERATIVE; DRUG MONITORING; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84922722917     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i6.1880     Document Type: Article

References (25)

1. Hanauer SB. Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment Pharmacol Ther 2008; 27 Suppl 1: 15-21 [PMID: 18307645 DOI: 10.1111/j.1365-2036.2008.03606.x]
2. Masson S, Nylander D, Mansfield JC. How important is onset of action in ulcerative colitis therapy? Drugs 2005; 65: 2069-2083 [PMID: 16225364 DOI: 10.2165/00003495-200565150-00001]
3. Faubion WA, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-260 [PMID: 11487534 DOI: 10.1053/gast.2001.26279]
4. Bianchi Porro G, Cassinotti A, Ferrara E, Maconi G, Ardizzone S. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther 2007; 26: 779-794 [PMID: 17767462 DOI: 10.1111/j.1365-2036.2007.03334.x]
5. Flanagan WM, Corthésy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991; 352: 803-807 [PMID: 1715516 DOI: 10.1038/352803a0]
6. Bamba S, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A. Immunomodulators and immunosuppressants for Japanese patients with ulcerative colitis. ISRN Gastroenterol 2011; 2011: 194324 [PMID: 21991497 DOI: 10.5402/2011/194324]
7. Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006; 55: 1255-1262 [PMID: 16484504 DOI: 10.1136/gut.2005.081794]
8. Ogata H, Kato J, Hirai F, Hida N, Matsui T, Matsumoto T, Koyanagi K, Hibi T. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2012; 18: 803-808 [PMID: 21887732 DOI: 10.1002/ibd.21853]
9. Marion JF, Rubin PH, Present DH. Differential Diagnosis of Chronic Ulcerative Colitis and Crohn's Disease. In: Kirsner JB, editor. Inflammatory Bowel Disease. 5th ed. Philadelphia, PA: WB Saunders, 2000: 315-325
10. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-1629 [PMID: 3317057 DOI: 10.1056/NEJM198712243172603]
11. Gavalas E, Kountouras J, Stergiopoulos C, Zavos C, Gisakis D, Nikolaidis N, Giouleme O, Chatzopoulos D, Kapetanakis N. Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients. Hepatogastroenterology 2007; 54: 1074-1079 [PMID: 17629042]
12. Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, Arts J, D'Hoore A, Penninckx F, Rutgeerts P. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-1031 [PMID: 14517785 DOI: 10.1016/S0016-5085(03)01214-9]
13. Yamamoto S, Nakase H, Mikami S, Inoue S, Yoshino T, Takeda Y, Kasahara K, Ueno S, Uza N, Kitamura H, Tamaki H, Matsuura M, Inui K, Chiba T. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008; 28: 589-597 [PMID: 18549460 DOI: 10.1111/j.1365-2036.2008.03764.x]
14. Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 2007; 132: 516-526 [PMID: 17258720 DOI: 10.1053/j.gastro.2006.12.037]
15. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-753 [PMID: 16698746 DOI: 10.1136/gut.2005.082909]
16. Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis 2008; 14: 7-12 [PMID: 17879277]
17. Högenauer C, Wenzl HH, Hinterleitner TA, Petritsch W. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 2003; 18: 415-423 [PMID: 12940927 DOI: 10.1046/j.1365-2036.2003.01662.x]
18. Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs: a review. J Am Soc Nephrol 1999; 10: 1366-1380 [PMID: 10361877]
19. Watson S, Pensabene L, Mitchell P, Bousvaros A. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflamm Bowel Dis 2011; 17: 22-29 [PMID: 20722055 DOI: 10.1002/ibd.21418]
20. Fellermann K, Tanko Z, Herrlinger KR, Witthoeft T, Homann N, Bruening A, Ludwig D, Stange EF. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002; 8: 317-324 [PMID: 12479646 DOI: 10.1097/00054725-200209000-00002]
21. Inoue T, Murano M, Narabayashi K, Okada T, Nouda S, Ishida K, Kawakami K, Abe Y, Takeuchi T, Tokioka S, Umegaki E, Higuchi K. The efficacy of oral tacrolimus in patients with moderate/severe ulcerative colitis not receiving concomitant corticosteroid therapy. Intern Med 2013; 52: 15-20 [PMID: 23291669 DOI: 10.2169/internalmedicine.52.8555]
22. Murano M, Inoue T, Narabayashi K, Nouda S, Ishida K, Kawakami K, Kuramoto T, Abe Y, Inoue T, Murano N, Morita E, Umegaki E, Higuchi K. The safety and efficacy of rapid induction therapy using tacrolimus for severe ulcerative colitis refractory to steroid therapy. Stomach and Intestine 2011; 46: 1957-1968
23. Schmidt KJ, Herrlinger KR, Emmrich J, Barthel D, Koc H, Lehnert H, Stange EF, Fellermann K, Büning J. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. Aliment Pharmacol Ther 2013; 37: 129-136 [PMID: 23121200 DOI: 10.1111/apt.12118]
24. Hirai F, Takatsu N, Matsui T. Letter: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2013; 37: 501 [PMID: 23336690 DOI: 10.1111/apt.12203]
25. Landy J, Wahed M, Peake ST, Hussein M, Ng SC, Lindsay JO, Hart AL. Oral tacrolimus as maintenance therapy for refractory ulcerative colitis - an analysis of outcomes in two London tertiary centres. J Crohns Colitis 2013; 7: e516-e521 [PMID: 23623737]